G PROTEIN COUPLED RECEPTOR;
GLYCOGEN SYNTHASE KINASE 3BETA;
LIGAND;
RETINA S ANTIGEN;
SEROTONIN RECEPTOR;
DRUG DEVELOPMENT;
DRUG SELECTIVITY;
HUMAN;
MENTAL DISEASE;
PRIORITY JOURNAL;
PROTEIN CONFORMATION;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
X RAY CRYSTALLOGRAPHY;
DRUG EFFECTS;
MENTAL DISORDERS;
METABOLISM;
DRUG DISCOVERY;
HUMANS;
LIGANDS;
MENTAL DISORDERS;
PROTEIN CONFORMATION;
RECEPTORS, G-PROTEIN-COUPLED;
Selective p38a MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction
Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB et al (2011). Selective p38a MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71: 498-511
Signalling bias in new drug discovery: Detection, quantification and therapeutic impact
Kenakin T, Christopoulos A (2013). Signalling bias in new drug discovery: Detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216
Serotonin, but not N-methyltryptamines, activates the serotonin 2 A receptor via a --Arrestin2/Src/Akt signaling complex in vivo
Schmid CL, Bohn LM (2010). Serotonin, but not N-methyltryptamines, activates the serotonin 2 A receptor via a --Arrestin2/Src/Akt signaling complex in vivo. J Neurosci 30: 13513-13524
Structural features for functional selectivity at serotonin receptors
Wacker D, Wang C, Katritch V, Han GW, Huang X-P, Vardy E et al (2013). Structural features for functional selectivity at serotonin receptors. Science 340: 615-619